193 related articles for article (PubMed ID: 33230308)
1. Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
Leitsalu L; Palover M; Sikka TT; Reigo A; Kals M; Pärn K; Nikopensius T; Esko T; Metspalu A; Padrik P; Tõnisson N
Eur J Hum Genet; 2021 Mar; 29(3):471-481. PubMed ID: 33230308
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
3. Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
Stefansdottir V; Thorolfsdottir E; Hognason HB; Patch C; van El C; Hentze S; Cordier C; Mendes Á; Jonsson JJ
Eur J Hum Genet; 2020 Dec; 28(12):1656-1661. PubMed ID: 32523053
[TBL] [Abstract][Full Text] [Related]
4. How to manage BRCA mutation carriers?
Sabiani L; Barrou J; Mathis J; Eisinger F; Bannier M; Lambaudie E; Houvenaeghel G
Horm Mol Biol Clin Investig; 2020 May; 41(3):. PubMed ID: 32459193
[TBL] [Abstract][Full Text] [Related]
5. Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
Ohneda K; Hamanaka Y; Kawame H; Fuse N; Nagami F; Suzuki Y; Yamaguchi-Kabata Y; Shimada M; Masamune A; Aoki Y; Ishida T; Yamamoto M
Breast Cancer; 2023 Jan; 30(1):110-120. PubMed ID: 36161580
[TBL] [Abstract][Full Text] [Related]
6. Identification and management of familial breast cancer in Austria.
Singer CF; Tan YY; Rappaport C
Horm Mol Biol Clin Investig; 2017 Nov; 32(2):. PubMed ID: 29190211
[TBL] [Abstract][Full Text] [Related]
7. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
8. Examining the uptake of predictive BRCA testing in the UK; findings and implications.
Martin AP; Downing J; Collins B; Godman B; Alfirevic A; Greenhalgh KL; Pirmohamed M
Eur J Hum Genet; 2021 Apr; 29(4):699-708. PubMed ID: 33328582
[TBL] [Abstract][Full Text] [Related]
9. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
10. Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.
Manickam K; Buchanan AH; Schwartz MLB; Hallquist MLG; Williams JL; Rahm AK; Rocha H; Savatt JM; Evans AE; Butry LM; Lazzeri AL; Lindbuchler DM; Flansburg CN; Leeming R; Vogel VG; Lebo MS; Mason-Suares HM; Hoskinson DC; Abul-Husn NS; Dewey FE; Overton JD; Reid JG; Baras A; Willard HF; McCormick CZ; Krishnamurthy SB; Hartzel DN; Kost KA; Lavage DR; Sturm AC; Frisbie LR; Person TN; Metpally RP; Giovanni MA; Lowry LE; Leader JB; Ritchie MD; Carey DJ; Justice AE; Kirchner HL; Faucett WA; Williams MS; Ledbetter DH; Murray MF
JAMA Netw Open; 2018 Sep; 1(5):e182140. PubMed ID: 30646163
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
12. The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
Menko FH; Jeanson KN; Bleiker EMA; van Tiggelen CWM; Hogervorst FBL; Ter Stege JA; Ait Moha D; van der Kolk LE
Eur J Hum Genet; 2020 Aug; 28(8):1020-1027. PubMed ID: 32300191
[TBL] [Abstract][Full Text] [Related]
13. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
14. Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
Moss HA; Samimi G; Havrilesky LJ; Sherman ME; Myers ER
Genet Epidemiol; 2018 Feb; 42(1):117-122. PubMed ID: 29193313
[TBL] [Abstract][Full Text] [Related]
15. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
16. The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
Neusser S; Lux B; Barth C; Pahmeier K; Rhiem K; Schmutzler R; Engel C; Wasem J; Huster S; Dabrock P; Neumann A
Curr Med Res Opin; 2019 Dec; 35(12):2103-2110. PubMed ID: 31394049
[No Abstract] [Full Text] [Related]
17. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
18. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
[TBL] [Abstract][Full Text] [Related]
19. Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees.
van Driel CMG; Oosterwijk JC; Meijers-Heijboer EJ; van Asperen CJ; Zeijlmans van Emmichoven IA; de Vries J; Mourits MJE; Henneman L; Timmermans DRM; de Bock GH
Breast; 2016 Dec; 30():66-72. PubMed ID: 27639031
[TBL] [Abstract][Full Text] [Related]
20. Surgical Management of Hereditary Breast Cancer.
Berger ER; Golshan M
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
